Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Nov 10;16(11):e73393.
doi: 10.7759/cureus.73393. eCollection 2024 Nov.

Cefepime-Induced Mixed Hepatocellular and Cholestatic Liver Injury: A Case Report

Mahyar Toofantabrizi  1 , Anuj Timshina  2 , Raj M Dongol  2
Affiliations
Case Reports

Cefepime-Induced Mixed Hepatocellular and Cholestatic Liver Injury: A Case Report

Mahyar Toofantabrizi et al. Cureus. .

Abstract

Drug-induced liver injury (DILI) presents significant diagnostic challenges, particularly in patients with multiple comorbidities. We report a case involving a 72-year-old female treated with cefepime for urosepsis, who developed markedly elevated liver enzymes after two weeks of therapy. After excluding other potential causes, including viral hepatitis, ischemia, and autoimmune hepatitis, cefepime-induced mixed pattern liver injury was determined to be the likely etiology of the elevated liver enzymes. This case underscores the importance of considering DILI in the differential diagnosis and emphasizes the necessity for vigilant monitoring and early recognition, particularly in elderly patients.

Keywords: cefepime; cholestatic injury; drug-induced liver injury (dili); hepatocellular injury; idiosyncratic.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

    1. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Chalasani N, Bonkovsky HL, Fontana R, et al. Gastroenterology. 2015;148:1340–1352. - PMC - PubMed
    1. Drug-induced liver injury: present and future. Suk KT, Kim DJ. Clin Mol Hepatol. 2012;18:249–257. - PMC - PubMed
    1. Drug-induced liver injury. David S, Hamilton JP. https://pubmed.ncbi.nlm.nih.gov/21874146/ US Gastroenterol Hepatol Rev. 2010;6:73–80. - PMC - PubMed
    1. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Andrade RJ, Lucena MI, Fernández MC, et al. Gastroenterology. 2005;129:512–521. - PubMed
    1. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Aliment Pharmacol Ther. 2005;129:512–521. - PubMed

Publication types

LinkOut - more resources